Quick Answer
Fulcrum Therapeutics, Inc. reported R&D Expense of $56.10 million for fiscal year 2025.
Fulcrum Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $56.10M | -11.5% |
| 2024 | $63.39M | -11.7% |
| 2023 | $71.80M | -6.5% |
| 2022 | $76.78M | +10.2% |
| 2021 | $69.70M | +18.1% |
| 2020 | $59.04M | -16.9% |
| 2019 | $71.07M | +182.2% |
| 2018 | $25.18M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $14.30M | -2.3% | +10.1% |
| June 30, 2025 | $12.99M | -24.8% | -3.1% |
| March 31, 2025 | $13.40M | -32.2% | -8.4% |
| September 30, 2024 | $14.64M | -19.7% | -15.2% |
| June 30, 2024 | $17.26M | -3.3% | -12.7% |
| March 31, 2024 | $19.77M | +18.3% | +8.4% |
| September 30, 2023 | $18.24M | +18.7% | +2.2% |
| June 30, 2023 | $17.85M | -28.7% | +6.8% |
- Fulcrum Therapeutics, Inc. showed a decrease of -11.5% in R&D Expense compared to the prior fiscal year.
- Over the 2018–2025 period, Fulcrum Therapeutics, Inc.’s r&d expense has grown by 122.8% (from $25.18 million to $56.10 million).
- The most recent figure is from Fulcrum Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: